NCT00118976View on ClinicalTrials.gov

Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

September 30, 2006

Conditions
Diabetes Mellitus, Type IDiabetic Nephropathy
Interventions
DRUG

Lisinopril

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

All Listed Sponsors
lead

Steno Diabetes Center Copenhagen

OTHER

NCT00118976 - Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease | Biotech Hunter | Biotech Hunter